
Please try another search
Trius Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibiotics for serious infections. It develops tedizolid phosphate that has completed phase 3 clinical trial for the treatment of acute bacterial skin and skin structure infections; and completed phase 1 clinical trial for the treatment of pneumonia. The tedizolid phosphate is a novel antibiotic for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant staphylococcus aureus. The company also develops GyrB/ParE, which are under preclinical program and are targets of the fluoroquinolone class of antibacterial agents, such as ciprofloxacin. Trius Therapeutics, Inc. was incorporated in 2004 and is headquartered in San Diego, California. Trius Therapeutics LLC operates as a subsidiary of Merck & Co., Inc.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review